Mathew Thomas

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Sandra Navarra, Renato Guzmán, A Gallacher et al. · The Lancet · 2011 · 2K citations

Medicine, Immunology, Pharmacology +11

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A

Flora Peyvandi, Pier Mannuccio Mannucci, Isabella Garagiola et al. · New England Journal of Medicine · 2016 · 491 citations · Full text

Medicine, Hematology, Immunology +16

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

William Stohl, Falk Hiepe, Kevin Latinis et al. · Arthritis & Rheumatism · 2012 · 416 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus

DJ Wallace, Sandra Navarra, M. Pétri et al. · Lupus · 2012 · 120 citations

Medicine, Pharmacology, Pharmacotherapy +13

Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension

Ronald van Vollenhoven, Sandra Navarra, Roger A. Levy et al. · Lara D. Veeken · 2019 · 86 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16